Surgify Medical develops bone-cutting technology and its flagship product, Surgify Halo, which differentiates hard and soft tissue to reduce incidental soft-tissue damage in head, neck and spine surgery. The company is led by CEO Visa Sippola and is headquartered in Espoo, Finland, with offices in Finland, Sweden, Denmark and the United States. Surgify intends to use its latest funding to expand operations across Europe and the U.S. The article states the product focuses on improving precision and streamlining bone-surgery procedures by providing enhanced soft-tissue protection. Financially, Surgify has raised a total of €14M to date, including the recent Series A. No additional operating metrics were provided in the article. Surgify Medical has developed a surgical drill intended to reduce nerve and blood-vessel injuries in bone surgeries across the head, neck and spine, and for dental procedures and surgical robotics. Patents and pre-clinical trials for the device were successful. The company received sales approval for its product in May. Surgify is focused on scaling production to meet demand from leading hospitals in the US and Europe that have already expressed interest. The firm plans to supply hospitals in Finland and across the Nordics next year, with broader international expansion to follow. Financially, the company recently secured external funding to support commercialization efforts.

Total raised

$10M

Funding rounds

2

Latest round

Series A

Latest activity

May 2025